Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29550566

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Eur J Cancer
Publication date
2018 May
First author
Choueiri TK

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Eur J Cancer. 2018 Nov;103:287. doi: 10.1016/j.ejca.2018.09.022.
    note
    Source null
    related pmid
    30270112
    relationship
    Erratum in

Authors and identifiers

  1. name
    Choueiri TK
    type
    Author
  2. name
    Hessel C
    type
    Author
  3. name
    Halabi S
    type
    Author
  4. name
    Sanford B
    type
    Author
  5. name
    Michaelson MD
    type
    Author
  6. name
    Hahn O
    type
    Author
  7. name
    Walsh M
    type
    Author
  8. name
    Olencki T
    type
    Author
  9. name
    Picus J
    type
    Author
  10. name
    Small EJ
    type
    Author
  11. name
    Dakhil S
    type
    Author
  12. name
    Feldman DR
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Choueiri TK
    type
    Author
  2. name
    Hessel C
    type
    Author
  3. name
    Halabi S
    type
    Author
  4. name
    Sanford B
    type
    Author
  5. name
    Michaelson MD
    type
    Author
  6. name
    Hahn O
    type
    Author
  7. name
    Walsh M
    type
    Author
  8. name
    Olencki T
    type
    Author
  9. name
    Picus J
    type
    Author
  10. name
    Small EJ
    type
    Author
  11. name
    Dakhil S
    type
    Author
  12. name
    Feldman DR
    type
    Author
bibliography ids
  1. nci-bib-c47f5948f372dec3984db612
book metadata
content sha256
0cd00988f07c396a9c6bb79d3bf35c81b412d58ddab5d9cc4ea75e8dafcd5a03
document type
citation
dois
  1. 10.1016/j.ejca.2018.02.012
electronic publication date
display
2018 Mar 20
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:29550566
immutable id
pubmed:29550566@0cd00988f07c396a9c6bb79d3bf35c81b412d58ddab5d9cc4ea75e8dafcd5a03
journal
abbreviation
Eur J Cancer
issn electronic
1879-0852
issn print
0959-8049
issue
Source null
name
European journal of cancer (Oxford, England : 1990)
nlm unique id
9005373
pages
115-125
volume
94
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Eur J Cancer. 2018 Nov;103:287. doi: 10.1016/j.ejca.2018.09.022.
    note
    Source null
    related pmid
    30270112
    relationship
    Erratum in
outcomes validated
false
pmid
29550566
provenance
batch id
ec9444d0f4cade22eb9f
provider
NCBI PubMed ESummary
record sha256
bd0fd5d09853a33de6215fa4fe5919492753a3a0c0e269e5e5a2933a70c56bc8
response sha256
6eef0d8cc09b77e73af656f6390cc734befb84fbc4c229b886e81e5d95bece31
retrieved at
2026-09-09T23:47:30.975610+00:00
publication date
display
2018 May
precision
month
year
2018
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, N.I.H., Extramural
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29550566/
title
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.

Preserved source evidence · Not medical advice